Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 23, Pages 3650-3656
Publisher
Wiley
Online
2016-08-03
DOI
10.1002/cncr.30231
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2016) J.-H. Yoon et al. ANNALS OF ONCOLOGY
- Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2016) N. J. Short et al. BLOOD
- Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
- (2015) D.-Y. Kim et al. BLOOD
- Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
- (2015) Y. Chalandon et al. BLOOD
- Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) Farhad Ravandi et al. CANCER
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) N. Daver et al. HAEMATOLOGICA
- Acute Lymphoblastic Leukemia, Version 2.2015
- (2015) Joseph C. Alvarnas et al. Journal of the National Comprehensive Cancer Network
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
- (2015) Elias Jabbour et al. LANCET ONCOLOGY
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) N. Daver et al. HAEMATOLOGICA
- Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
- (2014) K R Schultz et al. LEUKEMIA
- Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
- (2013) F. Ravandi et al. BLOOD
- UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
- (2013) A. K. Fielding et al. BLOOD
- Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2012) S Lee et al. LEUKEMIA
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) R. Foa et al. BLOOD
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
- (2011) Peter C. Austin MULTIVARIATE BEHAVIORAL RESEARCH
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- (2010) F. Ravandi et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now